Heron Therapeutics Inc. shares soared in the extended session Tuesday after the biotech said a mid-stage clinical study showed one of its products significantly lowered pain following bunion removal surgery. Shares of Heron jumped 29% to $43.43 on heavy volume. Heron said a clinical study of its anesthetic and anti-inflammatory drug HTX-011 administered through the company’s Biochronomer drug delivery technology significantly reduced pain in patients following bunion removal surgery compared with placebo.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News